Stock Taper
SCREENER COMPARE ANY 2 STOCKS
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
NASDAQ
$5.18
▲ UP 1.47% (0.07)

KEY STATISTICS

Market Cap$310.48 M
52w High$5.78
52w Low$2.20
Dividend Yield—
Frequency—
P/E-5.35
Volume154.43K
Shares Out.59.88M

COMPANY

LEADERSHIP

David Hochman
CHIEF EXECUTIVE
David Hochman

COMPENSATION 2026

Salary$595,000
Stock Awards$996,000
Incentive Plan Pay$309,400
All Other Comp.$12,075
Total$1,912,475

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 4, 2020
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
86

PRICE TARGET

Target High$13.00
Target Low$10.00
Target Median$11.50
Target Consensus$11.50

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$133.00K
NOV
9
MON

PRICE

$5.18 ▲ UP 1.47% (+$0.07)
$5.12$5.16$5.209:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM5.18

About Orchestra BioMed Holdings, Inc.

https://orchestrabiomed.com ↗

Orchestra BioMed Holdings, Inc. is a biomedical innovation company developing therapies like BackBeat CNT for hypertension and Virtue SAB for artery disease, with strategic partnerships with Medtronic and Terumo.

INDUSTRY

Biotechnology

A PRODUCT ORCHESTRA BIOMED HOLDINGS, INC. IS KNOWN FOR

Virtue Sirolimus AngioInfusion Balloon (SAB)
Virtue Sirolimus AngioInfusion Balloon (SAB)

The Virtue Sirolimus AngioInfusion Balloon is a Breakthrough Device-designated, non-coated drug-eluting balloon delivering extended-release sirolimus for atherosclerotic artery disease, with ongoing U.S. trials and a $30M partnership with Terumo.

COMPETITORS

COMPETITOR
ABT COMPARE
BDX COMPARE
BSX COMPARE
MDT COMPARE

Revenue by Products

IconPRODUCTQ1-2025Q2-2025Q4-2025Q2-2026
Product$136K $169K ▲$306K ▲$88K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
53
LISTED HERE
10
RANKED BY POSITION SIZE
VTI
0.00% · 1.5M
XSU.TO
0.01% · 820.0K
SURI
1.31% · 219.4K
SCHA
0.00% · 200.7K
GSSC
0.03% · 68.0K
XRSG.L
0.01% · 36.5K
RSSL
0.01% · 18.9K
IBBQ
0.02% · 3.7K
AVSC
0.00% · 3.2K
BIB
0.01% · 2.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
39.03%
HOLDERS
89
TOP 12 OF 89 · RANKED BY POSITION SIZE
Rtw Investments, LP
8.3M sh · $35.3M
Perceptive Advisors LLC
5.3M sh · $13.13M
Blackrock Inc.
1.9M sh · $15.2M
Vanguard Group Inc
1.6M sh · $6.66M
Alyeska Investment Group, L.P.
1.4M sh · $3.39M
Pathstone Holdings, LLC
1.0M sh · $2.49M
Propel Bio Management, LLC
896.7K sh · $3.83M
Affinity Asset Advisors, LLC
727.3K sh · $1.8M
Millennium Management LLC
702.5K sh · $2.99M
Blackrock, Inc.
664.3K sh · $1.65M
Geode Capital Management, LLC
485.5K sh · $2.06M
Knoll Capital Management, LLC
455.1K sh · $421.16K

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL OFFICER
Taylor Andrew Lawrence
Sale · 3.1K shares
2026-08-26
★
DIRECTOR, OFFICER: SEE REMARKS
Sherman Darren
Sale · 4.9K shares
2026-08-26
★
DIRECTOR, OFFICER: SEE REMARKS
Sherman Darren
Purchase · 2.0K shares
2026-08-26
★
OFFICER: PRINCIPAL ACCOUNTING OFFICER
Aiello Joshua
Sale · 203 shares
2026-08-26

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OVERWEIGHT 2
5 GRADES IN THE LAST 12 MONTHS
Piper Sandler OVERWEIGHT B. Riley Securities BUY HC Wainwright & Co. BUY Barclays OVERWEIGHT Chardan Capital BUY

SECTORS PEERS

PEERPRICE
AVTX$19.59COMPARE
PRLD$5.47COMPARE
ENTA$13.60COMPARE
IVVD$0.96COMPARE
IVA$4.71COMPARE
EPRX$6.67COMPARE
TARA$3.82COMPARE
PYXS$3.23COMPARE